Palmitoylethanolamide (PEA) reduces inflammation in cardiomyocytes and endothelial cells exposed to doxorubicin and trastuzumab through PPAR-a and NLRP3

23 May 2022 (08:30 - 19:45)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Comorbidities and special population Cardio-Oncology HFA Premium Access Heart Failure 2022